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Introduction: Biochemistry of Tartrate-Resistant Acid
Phosphatase Enzymes
The tartrate-resistant acid phosphatases (TRAPs) are a class of
metalloenzymes that catalyze the hydrolysis of various phos-
phate esters and anhydrides under acidic reaction conditions.
Because the bound metal ions confer an intense color on these
enzymes they are also known as purple acid phosphatases
(PAPs). Resistance to inhibition by high concentrations of the
competitive inhibitor L 1 tartrate distinguishes TRAP from acid
phosphatases of lysosomal or prostatic origin present in many
mammalian cells and tissues.58
TRAP enzymes have been isolated from many mammalian
sources, including: bovine24,89 and rat spleen49; the spleens of
patients affected with hairy cell leukemia63 and Gaucher’s dis-
ease99; human2,53 and rat bone3; and human lungs28 and placen-
ta.64 The TRAP purified from porcine allantoic fluid, which is
also known as uteroferrin, was originally recognized as an
abundant basic protein in uterine secretions induced by proges-
terone.21 The catalytic mechanism, structure, and properties of
the iron center of porcine TRAP have been studied extensively
by our group.10,18,61,62,122
Mammalian isolated TRAP enzymes all have similar physical
properties, including a molecular weight of about 35 kDa, a basic
isoelectric point (pI 7.6–9.5), and optimal enzyme activity at an
acidic pH. The enzyme can be isolated as a single chain polypep-
tide, but a dimeric nicked form arises from posttranslational
cleavage of the single chain enzyme. Cleavage occurs in an
exposed loop that is conserved in all mammalian TRAP enzymes
and leads to an increase in Vmax/kcat of the enzyme by an
unknown mechanism.29,51,59,80,89 Several proteolytic enzymes
are able to cleave the exposed loop, but only the cysteine
proteinases papain and cathepsin B have been able to cause
activation among several tested. Ljusberg et al.75 put forth the
view that TRAP, like several other hydrolases, is synthesized as
a relatively inactive proenzyme, and cleavage is the physiolog-
ical mechanism of proenzyme activation in osteoclasts.
Mammalian TRAP enzymes are glycoproteins and, like most
lysosomal enzymes, possess the mannose-6-phosphate lysosomal
targeting sequence, which must presumably be cleaved or mod-
ified to permit secretion. TRAP isolated from allantoic fluid of
the pig showed a single, unphosphorylated, high-mannose-type
oligosaccharide composed of five or six mannose residues and
two N-acetylglucosamine residues.8,98 In contrast, recombinant
porcine TRAP secreted by Chinese hamster ovary (CHO) cells
possessed N-linked, high-mannose oligosaccharide chains that
were phosphorylated and could not be dephosphorylated by
alkaline phosphatase treatment in vitro. This suggests that the
uteroferrin oligosaccharide phosphates were not exposed, per-
haps as a result of blocking by an N-acetylglucosamine residue.74
The glycoprotein structure of human bone TRAP was analyzed
by lectin binding and, in agreement with the prior analysis of
native uteroferrin, contained only N-linked high-mannose carbo-
hydrates,41 implying that the native secreted protein is normally
dephosphorylated. Analysis of TRAP activity present in electro-
phoretically separated human serum revealed two isoforms,
termed 5a and 5b, with each isoform having a different pH
optimum (5a: pH 4.9; 5b: pH 5.5–6.0).69 The carbohydrate
content of the isoforms also differed with only isoform 5a
containing sialic acid.68
TRAP contains two iron atoms at its active site, and the intense
purple color of the enzyme results from a tyrosinate Fe(III) charge
transfer. Reduction of the active site binuclear center to a mixed
valency Fe(III)-Fe(II) form is required for activation and this cor-
responds to a shift in color from purple to pink. Further reduction or
the presence of iron chelators can lead to reversible inactivation and
formation of a colorless form of the enzyme.44 The enzyme is also
inhibited noncompetitively by incubation with vanadate22 or simply
following more extended incubation at 37°C.44 The latter case at
least, produced a “yellowish” form of the enzyme.44 TRAP may
become irreversibly inactivated by oxidation in the presence of
ascorbate.9 The recent availability of monoclonal antibodies against
TRAP20,41,43,44,51,57 has permitted the identification of an inacti-
vated “yellowish” form of the enzyme as the major form in the
circulation.44
Enzyme Mechanism and Conservation of TRAP-like Enzymes
from Nonmammalian Sources
Purple acid phosphatase from the red kidney (RKBPAP) was the
first member of this family for which a crystal structure became
available.116 RKBPAP is a larger enzyme than the mammalian
PAPs (111 kDa dimer) and contains Fe(III)-Zn(II) at the active
site instead of Fe(III)-Fe(II). Only 3.1 Å separate the two metal
ions at the active site of RKBPAP and the amino acid residues
that provide the metal ligands are conserved across all known
members of the PAP family. The octahedral coordination of the
metals was presumed to be completed by a bridging hydroxo
group, a hydroxyl group coordinated to Fe(III), and a water
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molecule coordinated to Zn(II). These ligands were not visible on
the electron density map. A reaction mechanism of RKBPAP
was proposed in which initial binding of the phosphate ester to
Zn(II) displaces the bound H2O followed by displacement of the
alcoholic product by an Fe(III)-bound hydroxide ion.66
Sequence alignment of RKBPAP with porcine TRAP sug-
gested that RKBPAP is a good model for the structure and
mechanism of other acid phosphatases.67 We recently confirmed
this overall prediction with solution of the crystal structure of the
porcine enzyme at 1.5 Å resolution39 (Brookhaven Database,
Access Code 1ute). Together with other groups we produced
substantial amounts of recombinant mouse, rat, and human
TRAP in baculovirus expression systems.29,51,80 Although pre-
liminary crystallization appeared promising there was a consid-
erable delay between the availability of recombinant enzyme and
production of crystals of sufficient size and quality to permit
structure determination. In our studies, progress was assisted
greatly by the availability of abundant native porcine enzyme
from allantoic fluid and was expedited by prior knowledge that it
was possible to produce a very stable oxidized enzyme phosphate
complex.61 The crystal structure shown in Figure 1 reveals a
symmetry that was less evident in the plant enzyme structure, and
suggests that the binuclear iron center could have evolved from
the combination of two mononuclear metal-ion-binding sites.
The high-resolution structure revealed strong electron density
between the two irons in the active site, indicating the presence
of a bridging oxo/hydroxo group. Coincident solution of the
structure of recombinant rat TRAP at 2.3 Å resolution by another
group of investigators confirmed the overall conclusions from
the porcine structure.119
The combination of structural and mechanistic studies pro-
vides insight into the catalytic mechanism of PAPs. In the initial
step, the phosphate group of the substrate is coordinated to the
divalent metal ion. Stopped-flow measurements on the pig en-
zyme have indicated a rapid binding of phosphate to Fe(II),6
suggesting that this step is not rate-limiting. Formation of the
enzyme-substrate complex is followed by a nucleophilic attack
on the phosphorus leading to the release of the product alcohol.
The nature of the attacking group remains uncertain. Three
possible candidates have been proposed: (i) a terminal Fe(III)-
bound hydroxide66; (ii) a bridging hydroxide120; or (iii) a hy-
droxide residing in the second coordination sphere of Fe(III).81
The absence of burst kinetics in bovine TRAP indicates that the
nucleophilic attack is probably rate-limiting.82 In the final step of
catalysis the metal-bound phosphate group is released. Metal
replacement studies have indicated that the kcat value of the
hydrolysis is not affected by the nature of the trivalent metal
ion.81 This observation indicates that phosphate release is not
rate-limiting and suggests that no ligand substitution reaction
takes place at the trivalent site. The latter conclusion argues
against the proposition that the nucleophile is located in the first
coordination sphere of the binuclear center (see earlier).
With the rapid accumulation of DNA sequence information
from a diversity of organisms, sequences of cDNAs from many
different sources have become available. Alignment of some
known TRAP-like sequences is shown in Table 1. TRAP-like
enzymes are found in organisms ranging from Aspergillus sp.,
certain Mycobacteria, through primitive animals to higher plants
and mammals. The presence of related enzymes in intracellular
pathogens that infect macrophages could be related to viru-
lence.96 Otherwise, a detailed search of the complete Saccharo-
myces genome, completed Drosophila sequences, and several
bacterial genomes reveals no genes with conserved metal ion-
binding motifs.105 This suggests either that the function(s) per-
formed by TRAP are not absolutely required for all eukaryotic
cells, or that a nonpurple enzyme that is not detected with the
search motif performs the same function. In prokaryotes, TRAP
enzymes may not be required because these organisms lack an
acidic subcellular compartment in which such enzymes would be
active. TRAP enzymes are found in invertebrates such as C.
elegans, so the role TRAP carries out in animals is not restricted
to those creatures with bones. The alignment defines a signature
motif that can be used to identify new members of the gene
family, as they become evident in sequence databases. Among
the genes shown in Table 1 is a newly discovered class of plant
enzymes more closely resembling mammalian enzymes in terms
of signature motif and size;105—the archetype and first discov-
ered being from the Easter lily. Purification and characterization
of these mammalian-type plant enzymes is proceeding in our
laboratory. The function of purple plant phosphatases is un-
known, the only real clue being the fact that they are inducible in
some plants by phosphate deprivation.25,71 It is possible that
elucidation of their function may give insight into the role of
TRAP in mammals. Novel structural features of recently discov-
ered plant TRAP enzymes include membrane localization via a
GPI anchor in an enzyme purified from duckweed.85
Substrate Specificity of TRAP
TRAP can catalyze the hydrolysis of a wide range of phos-
phate monoesters and anhydrides, including the widely used
substrates b-umbelliferylphosphate, p-nitrophenolphosphate,
and pyrophosphate, with Km values at pH 4.9 in the millimolar
range.80 In our studies,86 and those of others,44 pig, mouse,
and human enzymes had specific protein tyrosine phosphatase
activity. With phosphotyrosylpeptide substrates, the apparent
Km was decreased to the micromolar range at pH 4.9 by
flanking charged amino acids and by a large hydrophobic group
(Fmoc) attached to the amino terminus of the peptide sub-
Figure 1. Crystal structure of porcine TRAP.39 The Fe(III) atom is
shown as a purple sphere, and the redox-active Fe atom as a red sphere.
The disulfide bond between Cys 141 and Cys 2000 is shown as a yellow
ball-and-stick model. To highlight the pseudo-symmetry of the porcine
TRAP molecule one half (residues 1–115 and 270–303) is colored
yellow and the other half (residues 116–269) is blue.
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strate.86 These findings suggest that TRAP could have a much
greater degree of substrate specificity than previously envis-
aged, and also indicate that specific active-site antagonists are
likely to be possible. Indeed, a series of noncleavable phos-
photyrosine analogs of the active peptide substrates were
found to be inhibitors, with Ki values at pH 4.9 in the
micromolar range (unpublished). The Ki values for these
inhibitors were reduced still further at pH 3.3. This is lower
than is normally used in TRAP assays, but the enzyme is
actually a more efficient catalyst at this pH.80 There is no
direct evidence that such a low pH is attained in the resorptive
vacuole of osteoclasts, which has been measured directly by
micropuncture32 and microelectrode112 to be approximately
pH 5. Osteoclasts possess a high-activity adenosine triphos-
phate (ATP)-dependent proton pump, which is absolutely
required for normal bone resorption.73 With vectorial secre-
tion of large numbers of protons, the local pH may be much
lower than is evident from bulk-phase measurements with
pH-sensitive dyes.56 The kidney bean enzyme was also shown
to be susceptible to pH-dependent inhibition by the same
peptide inhibitors (unpublished), supporting the view that it
provides a useful model for the mammalian enzyme. Others
have reported on the identification of a series of hydroxynaph-
thalene phosphonate inhibitors of TRAP with Ki values in the
micromolar range, which further supports the view that the
enzyme is a viable target for active-site antagonists.110
A separate class of substrates for TRAP may be sugar
phosphates, possibly in the specific context of glycoproteins.
Bresciani and von Figura16 provided evidence that TRAP is a
major enzyme responsible for hydrolysis of phosphate from
the mannose-6-phosphate targeting sequence attached to
lysosomal enzymes. The physiological importance of this
finding is difficult to assess given the high levels of en-
zyme activity that were required to observe hydrolysis of
mannose-6-phosphate.
Control of TRAP Gene Expression
Gene Structure and Transcription Control
In contrast to most plants studied, Southern blot experiments on
human,76 pig,74 and mouse19 have detected a single gene, and no
related sequences exist in any mammalian EST databases. The
human TRAP gene is located on chromosome 19 (19p13.2-
13.3)70,76 and in the syntenic region on mouse chromosome 9.38
The overall intron-exon structure of the mouse and human TRAP
genes is conserved; they contain five exons with the ATG
(“start”) codon at the beginning of exon 2.19,34 The axis of
symmetry of the protein structure lies at the boundary between
the exons in the mouse and human genes, which suggests that a
gene duplication event may have occurred during the evolution
of the TRAP gene. Transcription gives rise to a 1.5 kb mRNA
with an open reading frame of 969–975 bp encoding a 323–325
amino acid protein.19,34 The porcine gene is quite different in
intron-exon structure with only three exons.19
TRAP Expression in Osteoclasts
The promoter of the TRAP gene, flanking the noncoding exon 1,
has been characterized in the human and mouse genes. The
sequences of the mouse and human proximal promoters are
aligned in Figure 2. Several contradictory locations with regard
to the transcription start sites in mouse and human cell lines have
been reported,19,95 including a possible initiation within the first
intron.93 We have not been able to detect any transcripts initiat-
ing within the first intron in macrophages or osteoclasts by
reverse transcription-polymerase chain reaction (RT-PCR) or
RNase protection, but uncharacterized elements within the intron
are absolutely required for maximal activity of the upstream
promoter in transfected RAW264 cells (A.I.C., unpublished
observations). Recently, we revisited the issue of transcription
Table 1. Conserved sequences in plant, animal, and microbial tartrate-resistant acid phosphatases (TRAPs)a
Source 1 2 3 4 5 Length Accession
Animals Human GDWG 34 GDNFY 34 GNHD 87 VAGH 33 GHDH 325 P13686
Mouse GDWG 34 GDNFY 34 GNHD 89 VAGH 33 GHDH 327 Q05117
Rat GDWG 34 GDNFY 34 GNHD 89 VAGH 33 GHDH 327 P29288
Pig GDWG 34 GDNFY 34 GNHD 89 VAGH 33 GHDH 338 P09889
Cowb GDWG -- GDNFY -- GNHD -- VAGH 33 GHDH — Not available
Zebrafishc GDWG 34 GDNFY 33 GNHD ---- ---- — AI415792
C. elegans GDTG 33 GDNIY 33 GNHD 98 ISGH 32 GHDH 382 Z81494
Plants (A) Easter lily GDWG 29 GDNFY 33 GNHD 89 VGHH 33 GHDH 329 Not available
A. thaliana GDWG 29 GDNFY 33 GNHD 89 VVGH 33 GHDH 315 AF200827
Sweet potato GDWG 29 GDNFY 33 GNHD 89 VIGH 33 GHDH 313 AF236107
Soybean GDWG 29 GDNFY 33 GNHD 89 VIGH 33 GHDH 333 AF236108
Red kidney bean GDWG 29 GDNFY 33 GNHD 89 VVGH 33 GHDH 332 AF236109
Plant (B) A. thaliana GDLG 25 GDLSY 32 GNHE 79 VLVH 35 GHVH 469 Q38924
Sweet potato GDIG 25 GDLSY 32 GNHE 79 VLVH 35 GHVH 473 AF200825
Soybean GDLG 25 GDLSY 32 GNHE 79 VLMH 35 GHVH 464 AF200824
Red kidney bean GDLG 25 GDLSY 32 GNHE 79 VLMH 35 GHVH 459 P80366
Microorganisms Aspergillus sp. NDMG 25 GDLSY 84 GBHE 151 VMSH 33 GHIH 614 U18554d
Mycobacteria GDQS 40 GDLCY 31 GNHE 89 VCMH 35 GHEH 529 Z77724e
Synechocystis sp. GDIA 38 GDNQY 27 GNHE 72 AYWH 32 GHDH 326 D90900f
aFive conserved blocks of residues surround the seven metal-ligating residues (in bold). The numbers of residues between these blocks and total length
are indicated. Note the clear distinction between the small (A) and large (B) forms of enzyme in plants.
bDetermined by amino acid sequencing (incomplete).
cOnly partial sequence available.
dSequence from A. ficuum.
eSequence from M. tuberculosis.
fSequence from Synechocystis 6803.
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initiation using purified mouse osteoclasts, which express the
highest levels of TRAP mRNA compared with many murine
tumor cell lines, all of which express TRAP mRNA at detectable
levels. The data indicate that osteoclasts initiate transcription at
a single point, downstream of a variant TATA-like element that
is conserved between mouse and human, whereas nonosteoclasts
initiate transcription from a cluster of sites up to 100 bp upstream
(Figure 2).19 The same TATA variant (AATAAA) is found
upstream of the transcription start site of another osteoclast-
specific gene, cathepsin K.72 The results indicate that the gene is
controlled separately by a typical “house keeping”-type promot-
er-driving expression in most cells, and a more active TATA-
containing promoter used to direct high-level expression in
osteoclasts and probably also in subsets of macrophages. There is
relatively little sequence conservation upstream of the proximal
promoter region between mouse and human.94 Within the con-
served region, there are multiple purine-rich elements containing
the GGAA core required for recognition by members of the Ets
transcription factor family. Ets family transcription factors, par-
ticularly the macrophage-specific factor PU.1, have been as-
cribed in control of many macrophage-specific genes.90,100,101
Targeted disruption of the PU.1 gene also causes osteopetrosis
and failure of the osteoclast differentiation.117 In keeping with
such a role, we found that the TRAP promoter can be trans-
activated in transfections of the macrophage cell line RAW264
by both PU.1 and Ets-2, and that the former factor acts through
the conserved Ets element highlighted in Figure 2 (unpublished
data). Immediately 59 of this element there is an E-box motif
(CAnnTG), which we have found is a functional response ele-
ment for the microphthalmia transcription factor (MiTF).77 Mu-
tations in the MiTF gene cause osteoclast functional deficien-
cies115,121 such as selective downmodulation of both TRAP
mRNA expression and TRAP promoter activity in culture-de-
rived osteoclasts.77 MiTF could interact with PU.1 bound to the
adjacent site, because the factors can bind directly to each
other.104 Reddy et al.95 noted the presence of multiple binding
sites for the transcription factor C/EBPb (NF-IL6) in the mouse
promoter, a finding of particular interest given the abundant
evidence of the effects of interleukin-6 (IL-6)-type cytokines in
osteoclastic differentiation and function.79 We found that
C/EBPb trans-activates the TRAP promoter in transiently trans-
fected RAW264 macrophages (A.I.C. and D.A.H., unpublished
observations) although the cis-acting elements involved have not
been located.
TRAP Expression at Extraskeletal Sites
The TRAP from porcine uterus (uteroferrin) may contribute to
iron transport and metabolism.17 The pig has a noninvasive
epitheliochorial placenta, so this precise mode of iron transport is
unique to this class of mammals. Nevertheless, we have recently
discovered that both TRAP mRNA and protein are present at
very high levels in the earliest identifiable invasive trophoblasts
in the hemochorial placenta of the mouse (N.W., unpublished
observations). The enzyme was purified from human placenta,64
so the function and regulation defined in the pig could be partly
conserved in other mammals despite the differences in placental
architecture. The possibility that TRAP from other tissues is
involved in iron transport or storage has led several groups to
examine the regulatory influence of intracellular iron on TRAP
expression. Decreased levels of TRAP mRNA, resulting from
either decreased transcription or increased degradation, have
been observed in human peripheral mononuclear cells treated
with desferrioxamine, a potent iron-chelating agent.1,12 In addi-
tion, TRAP promoters of both species have been reported to be
regulated by iron in some cell lines,1,12,92 although we have not
been able to reproduce this finding in the murine macrophage
line RAW264 (A.I.C., unpublished observations). Reddy et al.91
reported that mouse TRAP promoter can be downmodulated by
hemin, and characterized the responsive element, GAGGC. Re-
cently, Fleckenstein et al.35 analyzed iron responsiveness in the
human TRAP promoter and confirmed that GAGGC tandem
repeat sequences represent hemin-responsive elements. Regula-
tion by iron would be consistent with the involvement of a
Figure 2. An alignment of the sequences of the murine and human TRAP proximal promoters. The proximal 59 flanking region of the mouse and human
TRAP genes are aligned and sequence identity is marked with a bullet. The variant TATA box is boxed with white text; the osteoclast transcription
start point, as determined by 59-RACE, is marked; the murine exon 1 sequence is shown in bold; the PU.1 binding site and the MiTF binding site are
boxed. Candidate Sp1 sites are underlined.
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redox-sensitive loop in TRAP regulation, which is relevant to the
roles of oxidants in bone resorption. It is not clear whether iron
or hemin regulation occurs in osteoclasts in vivo, nor whether
this contributes to the regulation of bone resorption.
During embryonic development of the mouse, TRAP mRNA
has been detected by whole-mount in situ hybridization in
trophoblasts, and at low levels in hepatic parenchymal cells, but
nowhere else until osteogenesis commenced (N.A., N.W., and
D.A.H., unpublished observations). As bones start to develop,
TRAP mRNA is detectable on unidentified cells associated with
early stages of endochondral ossification, later becoming pro-
gressively restricted to mononuclear and multinuclear cells that
coexpress other markers of osteoclasts.58 There is a detailed
report on the development expression of TRAP in cells associ-
ated with early stages of tooth formation in the mouse,103 with
TRAP-expressing cells appearing by E12, around bud-stage
molar teeth. Aside from intensely stained osteoclasts, TRAP has
been detected at high levels in the dental follicle and dental pilla
in developing molar teeth.58 A separate study documented the
increase in TRAP mRNA in embryonic rat calvariae from E5 to
E20.30
Within adult tissues, the cellular sites of TRAP expression
have been difficult to determine with confidence, because the
histochemical assay is not definitive for TRAP when used at the
limits of sensitivity. Angel et al.6 and Hayman et al.50 analyzed
TRAP in adult mouse tissues. Northern blot detected TRAP
mRNA in spleen, thymus, liver, lung, skin, kidney, stomach, and
small intestines, whereas transcripts were absent from testis,
brain, heart, and skeletal muscle. A combination of in situ
hybridization, immunohistochemical staining, and TRAP-activ-
ity staining of tissue sections established the nature of the
expressing cells.49 In bone, osteoclasts were strongly TRAP-
positive, but chondrocytes within the femoral metaphysis also
expressed high levels of mRNA. Overall, results have shown
that, apart from macrophages and osteoclasts, TRAP is selec-
tively expressed in Langerhans cells/dendritic cells, and in a
number of other cell types of nonhematopoietic origin, including
selected chondrocytes, alveolar cells, renal tubular cells, and
some hepatic parenchymal cells. These abundant nonhematopoi-
etic cells probably contribute a significant proportion of the total
activity/mRNA levels in the major organs studied.
We have made transgenic mice overexpressing TRAP from
its own promoter.5 The transgenes elicited a copynumber-depen-
dent increase in both mRNA and protein levels in all tissues.
Apart from osteoclasts, tissue macrophages, particularly alveolar
and splenic macrophages, expressed abundant TRAP protein that
was elevated further in the transgenic animals. Among nonmem-
bers of the mononuclear phagocyte system, hepatic parenchymal
cells and renal glomerular cells (probably mesangial cells) con-
stitutively expressed detectable TRAP enzyme activity, increas-
ing in a graded fashion with increased transgene copynumber.
With the exception of glomerular mesangial expression, which is
clear in both wild-type and transgenic animals, the patterns of
expression were similar to those observed by Hayman et al.49
Independently, a TRAP promoter transgene driving the src pro-
tooncogene has also been shown to target expression to liver and
kidney.109 The generation of TRAP transgenic mice expressing
the SV40 large T antigen, with or without the bcl-XL antiapop-
totic gene, did not transform cells outside the osteoclast lin-
eage.14,54 The TRAP promoter has also been used to target
overexpression of the c-fos gene to osteoclasts to generate a
mouse model with some characteristics of Paget’s disease.11
Although Langerhans cells in the skin express TRAP,49 the
gene is also expressed in keratinocytes, and was shown to be
elevated in the transgenic animals.6 The enzyme has been local-
ized to keratohyalin granules in the granular layer and cornified
cells in the lower part of the stratum corneum, where it was
considered an important phosphoprotein phosphatase.88 The re-
ported detection of TRAP activity in the urothelium106 suggests
that expression of TRAP in cornified epithelium also occurs in
humans. TRAP expression in all these sites outside the mono-
nuclear phagocyte system could be simply an indication of high
levels of lysosomal activity, or the enzyme could have a specific
function that has not yet been determined. No overt defect in any
organ other than bone has been detected in TRAP null mice, or
in our TRAP overexpressing mice, but without knowing the
physiological substrate(s) the nature of such a defect is impos-
sible to predict. Furthermore, some functions of TRAP might be
carried by an unrelated enzyme, lysosomal acid phosphatase.
Function of TRAP in Osteoclastic Bone Resorption
Correlation Between TRAP Activity and Bone Resorption
By far the greatest interest in the biochemistry of mammalian
TRAP relates to its use as a marker for osteoclasts, the cells that
resorb bone. The relative specificity of TRAP as an osteoclast
marker, its proposed involvement in the resorptive process, and
its abundance have suggested that it could be used as a serum
marker for bone resorptive activity in pathological states such as
osteoporosis. Measurement of serum enzyme activity was con-
founded by the difficulty of excluding other phosphatases. After
an initial enzyme capture assay using antibodies against the
porcine enzyme27 was used, several groups have developed
monoclonal antibodies and enzyme-linked immunosorbent as-
says (ELISA).20,45–47,51,57 In all of these studies there was
evidence of elevation of total immunoreactive TRAP in a range
of states where osteoclastic activity is elevated, including grow-
ing children and postmenopausal women, as well as in Gaucher’s
and Paget’s diseases. Serum TRAP however, was shown to be a
poor indicator of bone turnover in response to antiresorptive
therapy.48 Brehme et al.15 noted that much of the TRAP in the
circulation forms inactive complexes with the proteinase inhib-
itor a2-macroglobulin, which may confound the use of TRAP as
a marker of bone turnover. Recently, a new serum TRAP assay
has been developed that combines enzyme capture with the
monoclonal antibody O1A and isoform 5b-specific assay condi-
tions.42 This assay indicates that the TRAP 5b isoform is oste-
oclastic in origin, whereas the 5a isoform is nonosteoclastic and
that isoform 5b does in fact provide an indicative marker of
osteoclastic resorptive activity.42
Requirement for TRAP Activity in Osteoclastic Bone
Resorption
The most direct in vitro evidence supporting a role for TRAP in
bone resorption has come from osteoclasts cultured on cortical
bone slices. Addition of anti-TRAP antibodies reduced the in
vitro resorption of bone,84,123 an observation we have repro-
duced using antiserum raised against recombinant murine TRAP
(A.I.C., unpublished observations). Addition of bisphosphonate
drugs or molybdate to the culture medium was also found to
reduce both TRAP activity and bone resorption.84 In the some-
what more complex mouse calvarial calcium-release assay, hy-
droxynaphthalene-phosphonate inhibitors of TRAP also inhib-
ited bone resorption.110
Mice with even a heterozygous null mutation introduced into
the TRAP gene showed evidence of mild osteopetrosis, which
was presumed to be due to defective osteoclastic remodeling
activity.52 Homozygous TRAP-deficient mice also exhibited
abnormal endochondral ossification, which probably reflects the
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high expression of TRAP in chondroclasts at the chondro-osseus
boundary during development,87 and indicates that TRAP is
required for normal mineralization of developing bone as well
as for maintaining adult bone integrity through continual
remodeling.
As noted earlier, we produced transgenic animals in which
tissue-specific overexpression of the TRAP gene was observed in
the multiple cell lineages that normally express the gene, includ-
ing osteoclasts. The animals were mildly osteoporotic, with
decreased density of trabeculae with the bone space in long
bones, but examination of the rate of bone formation and other
indices of osteoblast activity has shown that compensation for
increased osteoclast activity occurs through an increase in bone
mineralization rate.5 By analogy, the TRAP knockout mouse
almost certainly ameliorates the potential phenotypic effects of
the mutation and consequent osteoclast defect by decreasing the
rate of mineralization and/or increasing the number of osteoclasts
to compensate for their lack of function. To some extent, com-
pensation also occurs through the ability of lysosomal acid
phosphatase to substitute for TRAP. In contrast to the TRAP
knockout, targeted disruption of lysosomal acid phosphatase
causes a lysosomal storage disease,102 together with minor bone
abnormalities. The double knockout in which both genes are
mutated was claimed to have a more severe osteopetrotic phe-
notype,102 but the data have not been published. The combined
evidence from regulation, inhibition, and transgenic studies in-
dicates that TRAP is a “rate-limiting” enzyme in bone resorption,
but overexpression or absence of the gene during development
can be partly compensated by homeostatic processes. It must be
recognized that the transgenic animal data do not argue against
TRAP as a drug target. Currently, we have no information on the
effects of specific TRAP inhibitors on bone homeostasis in an
intact animal, but inhibitor studies in vitro remain promising.
Mechanistic Role of TRAP in Bone Resorption
TRAP as a Phosphoprotein Phosphatase
The bone matrix phosphoprotein, osteopontin, has been shown to
bind to osteoclast cell surface integrins via an RGD motif,
thereby mediating substrate adhesion, at least in vitro.36 Ek-
Rylander et al.31 found that osteopontin is a substrate for the
phosphoprotein phosphatase activity of osteoclast TRAP in vitro,
resulting in dephosphorylation of serine residues. Other phos-
phatase enzymes, including alkaline phosphatase and prostatic
acid phosphatase, lacked this enzymic activity. Following de-
phosphorylation of osteopontin by TRAP, it was no longer able
to support osteoclast-substrate binding,31 suggesting that TRAP
could regulate osteoclast adhesion to the bone surface. This
effect would not necessarily inhibit resorption; detachment could
permit osteoclasts to migrate across the bone surface to new
resorptive sites. Osteopontin is itself an osteoclast product se-
creted into the resorption space7,26,60,83,118 and is also a potent
inhibitor of de novo hydroxyapatite nucleation and crystal
growth. Dephosphorylation of osteopontin also abolishes this
inhibitory effect,13,55 although the consequences of this activity
for resorption are unclear. The major matrix protein, osteonectin,
is also a TRAP substrate,4 so the major function of TRAP in
resorption may simply be the catabolic degradation of bone
matrix phosphoproteins, thereby aiding access by specific pro-
teinases. This is similar to the function proposed for TRAP in the
degradation of red cell membrane and cytoskeletal phosphopro-
teins during erythrophagocytosis by macrophages.107
Other Possible Functions of TRAP Enzymes
An alternative, but not mutually exclusive, model for TRAP
function in bone resorption is based on the observation that the
enzyme is able to catalyze the generation of reactive oxygen
species (ROS). Because TRAP in its native reduced form has an
Fe(III)-Fe(II) active site, the ferrous ion is able to act as an
electron donor. The relevant reactions involved in the generation
of ROS, known as Haber–Weiss–Fenton chemistry, are shown as
follows:
Hydroxyl radical formation:
TRAP-Fe(III)-Fe(II) 1 H2O2 ’ TRAP-Fe(III)-Fe(III)
1 OH• 1 OH2
TRAP regeneration:
TRAP-Fe(III)-Fe(III) 1 O22 ’ TRAP-Fe(III)-Fe(II) 1 O2
Osteoclasts possess the same NADPH-oxidase-dependent su-
peroxide-generating system utilized by macrophages and granu-
locytes to generate free radicals for microbial killing.113,114
There is clear evidence that oxygen free radicals are produced at
the resorptive interface with bone and are required for active
resorption.23,40,65,97 The potential activity of TRAP as a Fenton
catalyst was recognized in studies of the porcine enzyme.111
Hayman et al.51 demonstrated that recombinant human TRAP is
able to catalyze iron-dependent peroxidation of luminol, which
can be monitored as chemiluminescence, independent of phos-
phatase activity. Similarly, Halleen et al.46 reported that
RAW264 macrophages overexpressing TRAP produced reactive
oxygen metabolites. More recently, this group reported that ROS
can be targeted to destroy collagen and other proteins in resorb-
ing osteoclasts. TRAP was found in transcytotic vesicles trans-
porting matrix degradation products through the cell.47 This
suggests that TRAP-generated ROS can participate in bone
matrix degradation not only in resorption lacunae but also intra-
cellularly in transcytotic vesicles. This mechanism could be
important in tissue remodeling and as an adjunct defense mech-
anism in TRAP-expressing phagocytic cells.47
As noted earlier, the purified porcine enzyme is irreversibly
inhibited when treated with hydrogen peroxide in the presence of
ascorbate. The Fe(III)-Zn(II) derivative of the enzyme was stable
under the same conditions. The results are consistent with the
generation of hydroxyl radicals by the enzyme, and subsequent
inactivation as a result of reaction of the hydroxyl radicals with
active-site residues.9 The presence of the inactive form of TRAP
in the circulation (see earlier) could be indirect evidence that a
strong oxidative environment occurs during bone resorption in
vivo and may also suggest a simple mechanism of feedback
regulation of TRAP enzyme activity by product inhibition.
Among its range of established substrates, TRAP has long
been known to be capable of hydrolyzing pyrophosphate.37
Pyrophosphate is a known inhibitor of bone resorption,108 so
pyrophosphate activity of TRAP per se could lead to an increase
in bone resorption by osteoclasts. The bisphosphonates are a
class of antiosteoporotic drugs with structures analogous to
pyrophosphate; the P-O-P structure is replaced by a nonhydro-
lyzable P-C-P. In principle, the bisphosphonates could act as
substrate analog TRAP inhibitors, but etidronate, a commonly
used bisphosphonate, is a relatively poor inhibitor of TRAP.2 We
also found no correlation between biological activity of bisphos-
phonates and TRAP-inhibitory activity (unpublished observa-
tions). Bisphosphonates act more globally on osteoclast viability.
Nitrogen-containing bisphosphonates, such as alendronate, iban-
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dronate, and risedronate, inhibit posttranslational prenylation of
Ras in osteoclasts, which leads to apoptosis.78 In the case of
alendronate at least this results from the inhibition of an uniden-
tified enzyme involved in the conversion of mevalonate to
geranylgeranyldiphosphate, the substrate for prenylation of most
GTP binding proteins.33
Directions for Future Research
Mammalian TRAP is clearly expressed at very high levels in
osteoclasts via the use of a separate conserved promoter. Teleo-
logically, it is difficult to believe that such specific expression
lacks a purpose. Transgenic mice, both knockouts and overex-
pressed, indicate that TRAP can be limiting for resorption. The
full extent of this role is probably masked by the ability of the
bone synthetic pathways to compensate for deficient resorption,
an observation that is hardly surprising given the tight homeo-
static control of serum calcium. Greater insight may come from
subjecting the animals to stresses such as ovariectomy or calcium
loading, or by crossing them to other stains that have altered bone
metabolism (e.g., op/op) or lower intrinsic bone mineral density
(e.g., C57BL/6). Ongoing studies of the active site of plant and
mammalian TRAP enzymes, and identification of high-affinity
substrates and inhibitors, suggest that active-site antagonists are
possible and might be candidate antiosteoporotic drugs.
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